Curated News
By: NewsRamp Editorial Staff
May 30, 2024
Immunic Inc CEO Daniel Vitt Highlights Advances in MS Treatment
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Immunic Inc's lead drug candidate, vidofludimus calcium, could become a critical tool in the fight against MS, offering a competitive advantage in MS treatment.
- Vidofludimus calcium works by activating a protein called Nurr1, providing direct neuroprotective effects in addition to its anti-inflammatory benefits via DHODH inhibition.
- The potential of vidofludimus calcium to transform MS treatment offers hope to millions of patients worldwide, making tomorrow better than today.
- Vidofludimus calcium's dual mechanism of action makes it a promising candidate for comprehensive MS treatment, with results expected in 2025 and 2026.
Impact - Why it Matters
The discussion of Immunic's innovative approach to MS treatment and the potential of vidofludimus calcium to transform MS treatment is crucial for patients, caregivers, and the medical community. The ongoing clinical trials and the drug's dual mechanism of action offer hope to millions of MS patients worldwide.
Summary
Immunic Inc CEO Daniel Vitt discussed the challenges and recent developments in treating multiple sclerosis (MS) in an interview with Proactive. Vitt emphasized the significant unmet medical need for effective treatments, noting that MS affects approximately 2.8 million people worldwide and often leads to progressive physical disability. He highlighted Immunic’s innovative approach to MS treatment, focusing on both inflammation and neuroprotection. The company’s lead drug candidate, vidofludimus calcium, is currently in clinical development for both relapsing and progressive forms of MS, with phase 3 and phase 2 trials underway.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Immunic Inc CEO Daniel Vitt Highlights Advances in MS Treatment
